Literature DB >> 2633919

Acid metabolite of progabide pharmacokinetics following single administration in the rabbit with special references to HPLC and (3H) muscimol radioreceptor assay.

C Brunet1, M Luyckx, M Lhermitte.   

Abstract

The aim of the present study was to monitor plasma levels of progabide and its metabolites in the rabbit following single oral administration of 20 mg.kg-1. The plasma levels were determined selectively using high performance liquid chromatography (HPLC) and then correlated with a global estimation by a (3H) muscimol radioreceptor assay (RRA). In our "in vitro" binding conditions progabide itself was virtually ineffective (IC50 greater than 100 microM) so only RRA active materiel plasma concentrations were studied. A good enough correlation (r = 0.71) has been established between HPLC and RRA plasma concentrations from 0 to 3 hours following oral administration specially considering the absorption phase. But with closed regards to the elimination pharmacokinetic parameters specially the elimination half-life values (t1/2el (RRA) = 1.67 h and t1/2el (HPLC) = 0.70 h) that correlation should be weaker than the former instead metabolites including GABAmide and GABA itself are probably present in amounts likely to affect the displacement of specific binding in the (3H) muscimol radioreceptor assay.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2633919     DOI: 10.1007/BF03190108

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  8 in total

1.  A simple, sensitive and specific radioreceptor assay for endogenous GABA in brain tissue.

Authors:  S J Enna; S H Snyder
Journal:  J Neurochem       Date:  1976-01       Impact factor: 5.372

2.  Properties of gamma-aminobutyric acid (GABA) receptor binding in rat brain synaptic membrane fractions.

Authors:  S J Enna; S H Snyder
Journal:  Brain Res       Date:  1975-12-12       Impact factor: 3.252

3.  gamma-Aminobutyric acid (GABA) receptor stimulation. III. Effect of progabide (SL 76002) on norepinephrine, dopamine and 5-hydroxytryptamine turnover in rat brain areas.

Authors:  B Scatton; B Zivkovic; J Dedek; K G Lloyd; J Constantinidis; R Tissot; G Bartholini
Journal:  J Pharmacol Exp Ther       Date:  1982-03       Impact factor: 4.030

4.  Determination of progabide and its acid metabolite in biological fluids by high-performance liquid chromatography on silica column with ultraviolet detection.

Authors:  V Ascalone; P Catalani; L Dal Bò
Journal:  J Chromatogr       Date:  1985-11-08

5.  gamma-Aminobutyric acid (GABA) receptor stimulation. II. Specificity of progabide (SL 76002) and SL 75102 for the GABA receptor.

Authors:  K G Lloyd; S Arbilla; K Beaumont; M Briley; G De Montis; B Scatton; S Z Langer; G Bartholini
Journal:  J Pharmacol Exp Ther       Date:  1982-03       Impact factor: 4.030

6.  Progabide reverses the nigral substance P reduction induced by chronic impairment of dopaminergic transmission.

Authors:  B Zivkovic; A Oblin; G Bartholini
Journal:  Eur J Pharmacol       Date:  1985-06-07       Impact factor: 4.432

7.  Evidence that SL75102 is an agonist at GABAb as well as GABAa receptors.

Authors:  N G Bowery; D R Hill; A L Hudson
Journal:  Neuropharmacology       Date:  1982-05       Impact factor: 5.250

8.  gamma-Aminobutyric acid (GABA) receptor stimulation. I. Neuropharmacological profiles of progabide (SL 76002) and SL 75102, with emphasis on their anticonvulsant spectra.

Authors:  P Worms; H Depoortere; A Durand; P L Morselli; K G Lloyd; G Bartholini
Journal:  J Pharmacol Exp Ther       Date:  1982-03       Impact factor: 4.030

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.